Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial.
Andrew M NaidechJames GrottaJordan ElmScott JanisDariush DowlatshahiKazunori ToyodaThorsten SteinerStephan A MayerPooja KhanolkarJulie DenlingerHeinrich J AudebertCarlos MolinaPooja KhatriNikola SpriggAchala VagalJoseph P BroderickPublished in: International journal of stroke : official journal of the International Stroke Society (2021)
In the US, FASTEST will be first NIH StrokeNet Trial with an Exception from Informed Consent which allows enrollment of non-communicative patients without an immediately identifiable proxy.
Keyphrases
- phase iii
- double blind
- placebo controlled
- open label
- clinical trial
- phase ii
- study protocol
- end stage renal disease
- randomized controlled trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- atrial fibrillation
- prognostic factors
- peritoneal dialysis
- healthcare
- health insurance
- smoking cessation
- patient reported
- subarachnoid hemorrhage